Camidanlumab tesirine

N/A

Report date: 2025/05/29 16:50:59

Base Information

Drug NameCamidanlumab tesirine
Drug Alias NameHuMax-TAC-ADCHuMax-TAC antibody and PBD warheadCamiADCT-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SCX payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agentsInterleukin-2 receptor alpha chain inhibitors
TargetsDNAInterleukin-2 receptor alpha chain
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesUrinary Bladder Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdc Therapeutics SaGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesAdc Therapeutics SaGenmab A/S
Inactive CompaniesN/A
Active IndicationsHodgkin Disease
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesUrinary Bladder Neoplasms +[17] 

Other Information

ATC CodeN/A
Related LinksN/A